Bedrijfsoverzicht
Silexion Therapeutics Corp is a biopharmaceutical entity dedicated to the discovery and development of RNA interference (RNAi)-based cancer drugs and delivery systems specifically designed to treat malignant solid tumors. The company operates within the healthcare sector, functioning specifically as a biotechnology firm that focuses on leveraging its proprietary LODER delivery platform to address therapeutic challenges in oncology. As of the latest available data, the company maintains a market capitalization of $3.50 million and employs a workforce of 13 individuals, while annual revenue figures are not currently reported in the financial records. This valuation and revenue profile indicate that Silexion is a micro-cap entity with limited scale, suggesting it is in an early-stage development phase where capital allocation is prioritized toward research and development rather than commercial revenue generation or market expansion. The small employee count relative to the industry average for clinical-stage biotechs further underscores the lean operational structure typical of companies focused on proprietary platform technology rather than broad product manufacturing.
Financiële gezondheid
The company reports no revenue on a trailing twelve-month basis, resulting in a net income of $-11,912,000 and an EBITDA of $-11,618,000, which highlights a cost structure dominated by high fixed costs associated with R&D and platform maintenance. The substantial gap between zero revenue and significant net losses reveals that the company is burning cash to advance its scientific pipeline rather than generating income from product sales. Free cash flow stands at $-6,507,125, indicating that the company's financial flexibility is currently constrained by its need to preserve cash reserves to fund ongoing operations and potential clinical trials. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the absence of commercial revenue to calculate profitability ratios at this stage of the business lifecycle. On the balance sheet, the company holds $5.99 million in cash against $2.04 million in debt, supported by a debt-to-equity ratio of 78.22, suggesting a leveraged position relative to equity but manageable given the cash runway. The current ratio is 2.41, which indicates a robust short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer against immediate financial obligations despite the lack of operating cash inflow. Return on Equity is not applicable due to the lack of earnings, while Return on Assets stands at -144.3%, a metric that reveals that the company's asset base is currently generating negative returns due to the heavy investment required before any commercial success.
Waarderingsbeoordeling
The trailing P/E ratio is not applicable given the negative earnings, whereas the forward P/E is listed as -1.64, a negative figure that implies the market is pricing in continued losses or that standard earnings-based valuation models are currently inappropriate for this stage of development. The price-to-book ratio is 1.26, which indicates that the market is valuing the company at a slight premium over its book value, potentially reflecting the perceived value of its proprietary LODER platform and intellectual property assets. The price-to-sales ratio is not applicable due to the absence of sales, and the EV/EBITDA ratio is 0.04, a metric that suggests the enterprise value is extremely low relative to earnings before interest, taxes, depreciation, and amortization, often seen in pre-revenue biotech firms with significant cash balances. Over the last 52 weeks, the stock has ranged between a low of $1.04 and a high of $22.36, meaning the current trading price sits significantly below the 52-week high, reflecting the high volatility and speculative nature of the asset class. The beta value is 0.06, which indicates that the stock's price volatility is virtually uncorrelated with the broader market movements, behaving more like an independent asset driven by specific biotech milestones rather than general market sentiment.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not applicable, as the company has not yet generated commercial revenue to establish a growth trajectory for comparison. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue because the denominator for such calculations is zero, implying that the traditional growth metrics used for mature companies do not apply to this pre-commercial entity. As the company does not pay a dividend, the dividend yield is not applicable and the payout ratio is 0.0%, indicating that all available cash flow is retained within the company to fund operations and development rather than being distributed to shareholders. The overall growth and income profile is characterized by a total lack of current income generation and traditional growth metrics, with the company's value entirely dependent on the future commercialization of its RNAi-based cancer drug portfolio and the successful execution of its clinical development program.